Future targets in the management of systemic sclerosis

Area of Science:

• Rheumatology
• Immunology
• Pathology

Background:

• Connective tissue diseases (CTDs), including systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), exhibit complex pathogeneses.
• These involve fibrosis, vascular dysfunction, immune system activation, and inflammation, presenting significant therapeutic challenges.

Purpose of the Study:

• To investigate potential therapeutic targets for CTDs, particularly SSc, given the limitations of current therapies.
• To elucidate the immunological aspects and fibrotic mechanisms underlying these diseases to identify novel treatment strategies.

Main Methods:

• Review of recent advances in understanding the immunological roles of B cells, T cells, matrix-remodelling cells, and autoantibodies in CTDs.
• Analysis of emerging knowledge regarding the mechanisms of fibrosis and vasculopathy in SSc.
• Evaluation of potential therapeutic approaches, including immunoablation, antioxidants, and endothelin receptor antagonists.

Main Results:

• Advances in understanding CTD immunology have enabled investigation of novel approaches like immunoablation.
• Mechanisms of SSc fibrosis are becoming clearer, revealing potential points for therapeutic intervention.
• Progress in understanding SSc vasculopathy suggests potential benefits from antioxidants and endothelin receptor antagonists.

Conclusions:

• Despite advances, CTDs remain challenging diseases with high morbidity and mortality.
• Identifying and targeting specific pathways in fibrosis, immune activation, and vascular dysfunction offers promising avenues for future therapies.